Medistem Reports Positive Multiple Sclerosis Data Using Fat Stem Cells
Medistem Inc. (PINKSHEETS: MEDS) announced today publication of a peer reviewed paper describing the scientific rationale and preliminary results of three patients with multiple sclerosis treated with their own fat derived stem cells.
[Read the full article here]Related News:
United Spinal Association Reports Positive Results of Stem Cell Transplantation to Treat Multiple Sclerosis: Study May …
Medistem Reports Rheumatoid Arthritis Patient Success Using Adult Stem Cell Protocol …
Medistem Reports Rheumatoid Arthritis Patient Success Using Adult Stem Cell Protocol